@BladderCaJrnl

BLC Journal | Dedicated to expediting our understanding & improving treatments of bladder and upper urinary tract cancers | Editors Seth Lerner, Dan Theodorescu

 SoMeEds
bladdercancerjournal.com/
Joined May 2015
  • Tweets2.1K
  • Following274
  • Followers2.3K
355Media
Stay updated with the latest content from our #BladderCancer journal by signing up to get news direct to your inbox. Go to: tiny.cc/BLCsignup Keep informed about new articles, challenging cases, reviews, & other features like our Clinical Trials Corner! #GoldOpenAccess
2
3
1,772
RESEARCH REPORT: BCG therapy for bladder cancer: Exploring patient experiences and concerns through artificial intelligence-based social media analysis by Zine-Eddine KHENE et al. journals.sagepub.com/doi/10.… @FaltasLab @Dan_Theodorescu @slernerbcmedu1

BCG therapy for bladder cancer: Exploring patient experiences and concerns through artificial...

Background There is a notable disparity between the guidelines for BCG therapy in non-muscle invasive bladder cancer (NMIBC). Reddit has emerged as a popular on...

journals.sagepub.com
2
4
305
SHORT COMMUNICATION: Achieving health equity in bladder cancer care: Addressing disparities through collaborative research and evidence-based strategies by Yelba Castellon-Lopez and Patricia Thompson. journals.sagepub.com/doi/ful… @FaltasLab @Dan_Theodorescu @slernerbcmedu1

Achieving health equity in bladder cancer care: Addressing disparities through collaborative...

The United States has seen a decrease in the incidence of bladder cancer and a decline in mortality rates over the past 20 years. However, not all groups have b...

journals.sagepub.com
1
2
246
The First Systematic Review and Meta-Analysis of Antiangiogenic Therapy Combined with Immune Checkpoint Inhibitors in Urothelial Cancer: Efficacy, Clinical Use and Future Applications by @mjmoussa_ et al. journals.sagepub.com/doi/ful… @FaltasLab @Dan_Theodorescu @slernerbcmedu1

Antiangiogenic therapy combined with immune checkpoint blockade in urothelial cancer: Systematic...

Background Antiangiogenic therapy had been tested in urothelial cancer (UC) without reaching the clinic. Objective We provide a systematic review and meta-anal...

journals.sagepub.com
1
5
9
770
REVIEW: Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma: evaluating treatment outcomes by Vera Rutten et al. journals.sagepub.com/doi/10.… @FaltasLab @Dan_Theodorescu @slernerbcmedu1

Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma:...

Background The presence of lymph node metastases in patients with urothelial carcinoma (UC) plays a pivotal role in disease management and prognosis. Patients w...

journals.sagepub.com
4
6
1,096
⚡️ On @EUplatinum - Intravesical durvalumab (1000 mg every 6 weeks) shows promise for high-risk NMIBC after BCG failure. - Feasible administration with negligible toxicity. - Encouraging efficacy as a localized immune checkpoint inhibitor. - Intravesical delivery may surpass systemic approaches. #BladderCancer #Immunotherapy @OncoAlert sciencedirect.com/science/ar…
1
21
48
3,469
🔥NOW in @BladderCaJrnl of @BladderCancerUS👉Can Combining ICIs w/ Antiangiogenic Agents Revive Antiangiogenic Therapy in Advanced Urothelial Cancer? @OAlhalabiMD @MDAndersonNews 1st Meta-Analysis: ORR 34% in ICI-naïve group vs 16% in ICI-exposed. Better patient selection🔑?
Omar Alhalabi, MD@OAlhalabiMD20 Dec 2024
hot-off-press📝antiangiogenics+immune checkpoint blockade in urothelial cancer: Sys rev and meta-analysis @mjmoussa_, @kovalenkojuls, @emanuele_crupi, E Proskuriakova, Y. Geng, @GFallara_MD, R. Benkhadra, @DanieleRaggi83, @DocMattCampbell @PavlosMsaouel journals.sagepub.com/doi/10.…

Antiangiogenic therapy combined with immune checkpoint blockade in urothelial cancer: Systematic...

Background Antiangiogenic therapy had been tested in urothelial cancer (UC) without reaching the clinic. Objective We provide a systematic review and meta-anal...

journals.sagepub.com
2
15
1
35
7,865
RESEARCH REPORT: North American Study and Meta-analysis Evaluating Performance of Bladder EpiCheck®, a FDA cleared test, in Non-Muscle Invasive Bladder Cancer Recurrence by Neil Fleshner et al. journals.sagepub.com/doi/ful… @FaltasLab @Dan_Theodorescu @slernerbcmedu1
3
4
336
Research Report: Repeat TURBT in large volume HG Ta NMIBC treated with induction BCG therapy was not associated with improved high-risk recurrence-free survival. @durant_adri et al. journals.sagepub.com/doi/ful…. @FaltasLab @Dan_Theodorescu @slernerbcmedu1

Repeat TURBT in large volume high-grade non-invasive bladder cancer - Adri M. Durant, Mimi Nguyen,...

Background The American Urological Association (AUA)/Society of Urology Oncology (SUO) guidelines recommend a repeat transurethral resection of bladder tumor (T...

journals.sagepub.com
1
3
196
RESEARCH REPORT: Effectiveness of prolonged antibiotic prophylaxis in radical cystectomy: preliminary analysis of the MACS randomized clinical trial by Mariya Berkut et al. pmc.ncbi.nlm.nih.gov/article…. @FaltasLab @Dan_Theodorescu @slernerbcmedu1

Effectiveness of Prolonged Antibiotic Prophylaxis in Radical Cystectomy: Preliminary Analysis of...

Standard 24-hour antibiotic prophylaxis is widely employed to minimize the risk of infection complications within 30 days following radical cystectomy. However, a considerable variety of protocols...

pmc.ncbi.nlm.nih.gov
1
2
260
SHORT COMMUNICATION: Lifestyle Advice to Patients with Bladder Cancer: A National Survey of Dutch Urologists by Ivy Beeren et al. pmc.ncbi.nlm.nih.gov/article… @FaltasLab @Dan_Theodorescu @slernerbcmedu1

Lifestyle Advice to Patients with Bladder Cancer: A National Survey of Dutch Urologists

Not much is known about the extent to which urologists discuss lifestyle with patients with bladder cancer (BC), despite patients considering urologists as an important source of information and...

pmc.ncbi.nlm.nih.gov
1
2
224
POSITION PAPER: Eligibility and endpoints for clinical trials in trimodality therapy for bladder cancer by @RonaldChenMD, @slernerbcmedu1, @sonpavde, @HimanshuNagarMD, @Parminder1699 et al. pmc.ncbi.nlm.nih.gov/article… @FaltasLab @Dan_Theodorescu

Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer

Trimodality therapy (TMT) is a viable option for muscle-invasive localized bladder cancer, providing an alternative to radical cystectomy in properly selected patients. The approval of novel therap...

pmc.ncbi.nlm.nih.gov
3
6
457
NEW REVIEW focusing on ctDNA👉Perioperative use of ctDNA to Guide Treatment for Urothelial Carcinoma: The Future is Now👈by @DrTylerStewart et al. pmc.ncbi.nlm.nih.gov/article… @DrChoueiri @FaltasLab @slernerbcmedu1

Perioperative Use of ctDNA to Guide Treatment for Urothelial Carcinoma: The Future is Now

 Muscle-invasive bladder cancer represents a potentially curable disease, yet often disease recurs and is ultimately fatal. Outcomes for patients with localized urothelial carcinoma are heterogeneous...

pmc.ncbi.nlm.nih.gov
1
2
5
298
New Research Report: A molecular urine assay to detect recurrences during surveillance of high-risk non-muscle invasive bladder cancer by @FCdeJong, @JoepJdeJong, et al. pmc.ncbi.nlm.nih.gov/article… @FaltasLab @Dan_Theodorescu @slernerbcmedu1

A Molecular Urine Assay to Detect Recurrences During Surveillance of High-Risk Non-Muscle Invasive...

High-risk non-muscle invasive bladder cancer (HR-NMIBC) patients require long-term surveillance with cystoscopies, cytology and upper tract imaging. Previously, we developed a genomic urine assay for...

pmc.ncbi.nlm.nih.gov
4
6
595
Happy to present the latest review in Bladder Cancer by @SandeepGurramMD and @RathiNityam from @NCICCR_UroOnc "Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer" discussing ✅Rationale for devices ✅Devices available ✅Mechanisms ✅Efficacy ✅Safety ✅Future Studies
3
5
1,493
⚡️ Bladder Adjuvant Radiation Therapy (BART): Acute and Late Toxicity From a Phase III Multicenter Randomized Controlled Trial #BladderCancer @docpriyamvada @VedangMurthy sciencedirect.com/science/ar…
10
1
22
2,173
In @Nature: Full text article "Leveraging programmed cell death signature to predict clinical outcome and immunotherapy benefits in postoperative bladder cancer." Click here to read it: nature.com/articles/s41598-0…

Leveraging programmed cell death signature to predict clinical outcome and immunotherapy benefits...

Scientific Reports - Leveraging programmed cell death signature to predict clinical outcome and immunotherapy benefits in postoperative bladder cancer

nature.com
3
3
844
The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution. 👇
Dr. Bishoy M. Faltas@FaltasLab9 Oct 2024
🚀Big News! Excited to share our work “The Interplay of Mutagenesis and ecDNA Shapes Urothelial Cancer Evolution” published in @Nature! nature.com/articles/s41586-0…
Artistic conceptualization of chromosomal DNA breakdown and extrachromosomal circular DNA (ecDNA). These ecDNA circles can drive resistance to therapy in bladder cancer. Credit: Ella Maru Studio, Inc. @Ella_Maru

ALT Artistic conceptualization of chromosomal DNA breakdown and extrachromosomal circular DNA (ecDNA). These ecDNA circles can drive resistance to therapy in bladder cancer. Credit: Ella Maru Studio, Inc. @Ella_Maru

1
3
337
⚡️ On @EUplatinum - Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma #BladderCancer @IverNordentoft @SiaLindskrog europeanurology.com/article/…
7
12
987
⚡️ Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy #BladderCancer @mjmoussa_ @OAlhalabiMD @PavlosMsaouel ⁩ @DocMattCampbell mdpi.com/1718-7729/31/6/254 ⁩ ⁦
11
1
22
2,481
Bladder Cancer retweeted
Roger Li@UrogerliMD30 Sep 2024
Out now @EUplatinum - our review of FGFR inhibition in #bladdercancer covering: 👉MoA of receptor mediated signaling 👉Incidence in UC 👉Impact on TiME 👉Clinical trials and results 👉Possible mech of resistance Prelude to #PrecisionMedicine in UC authors.elsevier.com/a/1js9L…
20
57
4,184
Load more